Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Dare Bioscience, Inc. logo

Dare Bioscience, Inc. (DARE) Stock Ticker

NASDAQ: DARE · Healthcare · Biotechnology
$0.7755+4.73%
USD · as of 2026-09-27 · market cap $11.6M
Open DARE in TickrDownload for iPhone

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full DARE picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on DARE
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Dare Bioscience, Inc.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

DARE stock facts

Ticker symbolDARE
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology
Market cap$11.6M
CEOSabrina Martucci Johnson
Employees23
HeadquartersSan Diego, CA, US
IPO date2014-04-10
Websitedarebioscience.com

What you can see for DARE on Tickr

Live DARE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the DARE report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Dare Bioscience, Inc.?

The ticker symbol for Dare Bioscience, Inc. is DARE, listed on the NASDAQ.

What is DARE?

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation…

HomeExploreMarketLists
All pages